Advancing Genomic Medicine Research (R01 Clinical Trial Optional) | RFA HG 23 032

Opportunity Information: Apply for RFA HG 23 032

The National Human Genome Research Institute (NHGRI) plans to fund research projects under the opportunity titled "Advancing Genomic Medicine Research (R01 Clinical Trial Optional)" (Funding Opportunity Number RFA-HG-23-032). This is an NIH discretionary grant using the R01 mechanism, aimed at pushing genomic medicine forward in practical, real-world clinical care settings. The central goal is to stimulate innovative research that clarifies when genomic information should be used, where it is most effective to use it, and how best to implement and share genomic data and genomic technologies in healthcare. A major emphasis is on ensuring that genomic medicine benefits everyone, including groups and communities that experience health disparities, such as racial and ethnic minority populations, people with lower socioeconomic status, underserved rural communities, and sexual and gender minority groups.

This opportunity is focused less on basic discovery of new genes and more on the implementation and integration of genomics into clinical care, including the systems, workflows, policies, communication strategies, and data-sharing practices that make genomic medicine usable, trustworthy, and equitable. Applicants are expected to propose research that generates evidence about best practices for deploying genomic tools in healthcare, understanding barriers and facilitators in different clinical environments, and improving how genomic results are communicated and shared among clinicians, patients, health systems, and potentially across institutions. Because it is labeled "Clinical Trial Optional," an application may include a clinical trial if it fits the research objectives, but a trial is not required; strong non-trial implementation or health services research designs can also be appropriate.

Eligibility is broad and includes many types of U.S.-based organizations: state, county, city, township, and special district governments; independent school districts; public and state-controlled institutions of higher education; private institutions of higher education; federally recognized Native American tribal governments; tribal organizations that are not federally recognized; public housing authorities and Indian housing authorities; nonprofits with or without 501(c)(3) status (as long as they are not institutions of higher education in those categories); for-profit organizations other than small businesses; small businesses; and other eligible entities. The FOA also explicitly highlights a range of additional eligible applicants that are often central to equity-focused and community-engaged genomic medicine work, including Alaska Native and Native Hawaiian Serving Institutions, Asian American Native American Pacific Islander Serving Institutions (AANAPISI), Hispanic-serving Institutions, Historically Black Colleges and Universities (HBCUs), Tribally Controlled Colleges and Universities (TCCUs), faith-based or community-based organizations, eligible federal agencies, regional organizations, Indian/Native American Tribal Governments other than federally recognized ones, and U.S. territories or possessions.

Foreign participation is restricted in specific ways. Non-domestic (non-U.S.) entities and non-domestic (non-U.S.) components of U.S. organizations are not eligible to apply as applicants. However, foreign components are allowed as defined under the NIH Grants Policy Statement, meaning a U.S. applicant organization can include certain foreign elements in the project when justified and compliant with NIH policy, even though a foreign institution cannot serve as the primary applicant.

The opportunity is associated with CFDA numbers 93.172 and 93.393 and lists an award ceiling of $500,000. The original closing date provided is 2025-02-11. Overall, the program is designed for teams that can combine genomics with clinical implementation expertise, health equity approaches, and real-world healthcare delivery knowledge, especially where the work can reduce disparities and improve how genomic medicine is responsibly used and shared in everyday clinical practice.

• The National Institutes of Health in the education, health sector is offering a public funding opportunity titled "Advancing Genomic Medicine Research (R01 Clinical Trial Optional)" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.172, 93.393.
• This funding opportunity was created on 2023-11-06.
• Applicants must submit their applications by 2025-02-11. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• Each selected applicant is eligible to receive up to $500,000.00 in funding.
• Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For-profit organizations other than small businesses, Small businesses, Others.

Apply for RFA HG 23 032

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: